Recommendation of the President – Keytruda (pembrolizumab)

On 31 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 12/2025 on the reimbursement of the medicinal product Keytruda (pembrolizumab) for the indication: “Treatment of patients with urothelial carcinoma (ICD-10: C61, C65, C66, C67, C68)”

Publication in Public Information Bulletin (BIP) >>